Abstract
2 min readHCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly and Company, AstraZeneca, Merck, Novo Nordisk and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, DKSH, Zuellig, Roche and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Kowa, Pfizer, Hanmi and Viatris. EW reports consulting fees from Novartis, AstraZeneca, Boehringer Ingelheim and Bayer. BC reports consulting fees from Amgen, Boehringer-Ingelheim, Cardurion, Corvia, Myokardia and Novartis. SH is an employee and shareholder of Sanofi. JJVMcM has received payments through Glasgow University from work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer and Theracos, and personal lecture fees from Corpus, Abbott, Hikma, Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director and Global Clinical Trial Partners (GCTP). LK has received speakers honoraria from Novo, Novartis, Bayer, Boehringer and AstraZeneca. APM reports personal fees from AstraZeneca, Bayer and Novartis for the participation in study committees, outside the present work. MCR reports grants to his institution from Eli Lilly and GlaxoSmithKline, and consulting fees from Eli Lilly, Adocia, Anjii, Sanofi and Xeres. JCT holds the Canada Research Chair in personalized and translational medicine and Université de Montréal endowed research chair in atherosclerosis and reports grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio and Sanofi, honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer, minor equity interest in DalCor Pharmaceuticals and is an author of patents on pharmacogenomics-guided CETP inhibition and use of colchicine after myocardial infarction (JCT has waived his rights in the colchicine patents). MAP reports research grant support to his institution from Novartis; is a consultant to: AstraZeneca, Boehringer Ingelheim and Eli Lilly Alliance, Corvidia, DalCor, GlaxoSmithKline, Lexicon, NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has equity in DalCor. RD, KD and JLP have no relevant disclosures. The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14954. The data that support the findings of this study are available from the corresponding author upon reasonable request, and subject to conditions determined by the ELIXA steering committee and sponsor. Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Discussion(0)
No comments yet. Be the first to comment.